Because TAU is a protein involved in multiple neurodegenerative diseases, such as FTD and PSP among others, in this study we addressed the possible implication of RIPK1 in tauopathies and the therapeutic potential of the specific inhibitor GSK2982772, which is currently being tested in clinical trials for inflammatory diseases (Tompson et al., 2021a; Tompson et al., 2021b; Weisel et al., 2021; Ludbrook et al., 2024), as a new therapeutic approach for tauopathies. This evidence concerns the gene RIPK1 and supranuclear palsy, progressive, 1.